Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Starting Feb. 1, 2026, nitisinone for tyrosinemia type 1 and alkaptonuria will be publicly funded, simplifying access for about 10 patients.

flag Starting February 1, 2026, Pharmac will fund nitisinone for people with rare disorders tyrosinemia type 1 and alkaptonuria, moving it from the Named Patient Pharmaceutical Assessment to the standard Pharmaceutical Schedule. flag This change simplifies access and removes the need for individual applications, benefiting about 10 patients in the first year. flag The drug, used with a special diet, helps prevent toxic substance buildup. flag Current patients will transition to the LogixX Pharma brand, with alternatives available under Exceptional Circumstances if needed. flag Clinicians support the move for improved access and reduced administrative work.

3 Articles